Sermorelin
Sermorelin acetate (GHRH 1-29)
Sermorelin is a synthetic 29-amino acid peptide that mimics the biologically active portion of growth hormone releasing hormone (GHRH). Originally FDA-approved in 1997 as Geref® for treating children with growth hormone deficiency, it stimulates the pituitary gland to produce natural growth hormone in physiological pulsatile patterns. Unlike direct growth hormone injections, sermorelin works with the body's feedback mechanisms to prevent overdose and maintain natural GH rhythms.
Sermorelin Dosing Guide
Primary Benefits
- FDA-approved safety profile (originally Geref® 1997)
- Stimulates natural pulsatile GH release patterns
- 152% increase in growth velocity (pediatric studies)
- 12.3% increase in lean body mass (adult studies)
- 18.7% reduction in visceral fat accumulation
How It Works
Sermorelin functions as a synthetic analog of the first 29 amino acids of endogenous growth hormone releasing hormone (GHRH). It binds specifically to GHRH receptors (GHRHR) on somatotroph cells of the anterior pituitary gland, activating adenylyl cyclase and increasing intracellular cAMP levels. This cascade stimulates transcription of the growth hormone gene and promotes GH synthesis and secretion in natural pulsatile patterns. The physiological regulation via somatostatin feedback prevents excessive GH release and maintains the integrity of the growth hormone neuroendocrine axis, unlike exogenous recombinant GH administration.
Quick Reference
Typical Dosage Range
Standard sermorelin dosing follows a gradual escalation protocol starting at 100 mcg nightly for weeks 1-2 to assess tolerance, advancing to 200 mcg nightly (standard therapeutic dose) for weeks 3-4, with potential increase to 300 mcg nightly for enhanced response if needed. Maintenance dosing typically involves 200-300 mcg administered 5 nights per week with 2 non-consecutive rest days to prevent receptor downregulation. All doses are administered via subcutaneous injection 30 minutes before bedtime on an empty stomach (2+ hours after last meal). Pediatric dosing for FDA-approved use was weight-based at 30 mcg/kg daily. IGF-1 monitoring guides dose optimization.
Administration Methods
Sermorelin requires subcutaneous injection using 29-30 gauge insulin syringes into fatty tissue areas. Recommended injection sites include lower abdomen (2 inches from navel), anterior thigh, or posterior upper arm. Site rotation is essential to prevent lipodystrophy or injection site reactions. Proper injection technique involves pinching skin fold, inserting needle at 45-90 degree angle, aspirating to ensure no blood return, injecting slowly over 5-10 seconds, and applying gentle pressure post-injection. Reconstitution requires sterile bacteriostatic water, gentle mixing to avoid foam formation, and immediate refrigeration. Each vial typically provides 30-day supply when properly stored.
Medical Disclaimer
Clinical data presented is from peer-reviewed studies. Individual results may vary. Consult healthcare professionals before starting treatment. This information is for educational purposes only.